WO2004108940A3 - Produits - Google Patents

Produits Download PDF

Info

Publication number
WO2004108940A3
WO2004108940A3 PCT/GB2004/002387 GB2004002387W WO2004108940A3 WO 2004108940 A3 WO2004108940 A3 WO 2004108940A3 GB 2004002387 W GB2004002387 W GB 2004002387W WO 2004108940 A3 WO2004108940 A3 WO 2004108940A3
Authority
WO
WIPO (PCT)
Prior art keywords
viral genome
insertion site
genome vectors
relates
genome
Prior art date
Application number
PCT/GB2004/002387
Other languages
English (en)
Other versions
WO2004108940A2 (fr
Inventor
Michael Anthony Skinner
Michael Keith Howard
Joerg Schneider
Stephen Mark Laidlaw
Original Assignee
Oxxon Therapeutics Ltd
Inst Of Animal Health
Skinner Michael A
Michael Keith Howard
Joerg Schneider
Stephen Mark Laidlaw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxxon Therapeutics Ltd, Inst Of Animal Health, Skinner Michael A, Michael Keith Howard, Joerg Schneider, Stephen Mark Laidlaw filed Critical Oxxon Therapeutics Ltd
Publication of WO2004108940A2 publication Critical patent/WO2004108940A2/fr
Publication of WO2004108940A3 publication Critical patent/WO2004108940A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un acide nucléique de recombinaison comprenant un génome viral dans lequel a été insérée une séquence nucléotidique hétérologue, l'insertion étant située sur un site naturel de délétion ou d'insertion dudit génome. Dans un mode de réalisation préféré, le site d'insertion est pris dans la table 2, ou dans un homologue de ladite table. L'invention concerne également des virus contenant lesdits acides nucléiques.
PCT/GB2004/002387 2003-06-04 2004-06-04 Produits WO2004108940A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0312803.0 2003-06-04
GB0312803A GB2402391A (en) 2003-06-04 2003-06-04 Fowlpox recombinant genome

Publications (2)

Publication Number Publication Date
WO2004108940A2 WO2004108940A2 (fr) 2004-12-16
WO2004108940A3 true WO2004108940A3 (fr) 2005-04-21

Family

ID=9959297

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/002387 WO2004108940A2 (fr) 2003-06-04 2004-06-04 Produits

Country Status (2)

Country Link
GB (1) GB2402391A (fr)
WO (1) WO2004108940A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0517292A1 (fr) * 1991-05-27 1992-12-09 SOLVAY (Société Anonyme) Virus de l'Avipox recombinant
WO1996040880A1 (fr) * 1995-06-07 1996-12-19 Syntro Corporation Virus de variole aviaire recombines et leurs utilisations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
EP1450854A2 (fr) * 2001-11-30 2004-09-01 Isis Innovation Limited Vaccin
GB2382578A (en) * 2001-11-30 2003-06-04 Isis Innovation Fowlpox-based vaccine
AU2003236646B2 (en) * 2002-05-16 2009-01-15 Bavarian Nordic A/S Recombinant poxvirus expressing homologous genes inserted into the poxviral genome

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0517292A1 (fr) * 1991-05-27 1992-12-09 SOLVAY (Société Anonyme) Virus de l'Avipox recombinant
WO1996040880A1 (fr) * 1995-06-07 1996-12-19 Syntro Corporation Virus de variole aviaire recombines et leurs utilisations

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
AFONSO C L ET AL: "The genome of fowlpox virus", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 74, no. 8, April 2000 (2000-04-01), pages 3815 - 3831, XP002229418, ISSN: 0022-538X *
ANTOINE G ET AL: "The complete genomic sequence of the modified vaccinia Ankara strain: Comparison with other orthopoxviruses", VIROLOGY, vol. 244, no. 2, 10 May 1998 (1998-05-10), pages 365 - 396, XP002299585, ISSN: 0042-6822 *
BINNS M M ET AL: "ANALYSIS OF THE FOWLPOX VIRUS GENOME REGION CORRESPONDING TO THE VACCINIA VIRUS D6 TO A1 REGION LOCATION OF AND VARIATION IN NON-ESSENTIAL GENES IN POXVIRUSES", JOURNAL OF GENERAL VIROLOGY, vol. 71, no. 12, 1990, pages 2873 - 2882, XP009037559, ISSN: 0022-1317 *
BOULANGER DENISE ET AL: "Generation of recombinant fowlpox virus using the non-essential F11L orthologue as insertion site and a rapid transient selection strategy.", JOURNAL OF VIROLOGICAL METHODS, vol. 106, no. 1, October 2002 (2002-10-01), pages 141 - 151, XP002299584, ISSN: 0166-0934 *
BOURSNELL M E G ET AL: "INSERTION OF THE FUSION GENE FROM NEWCASTLE DISEASE VIRUS INTO A NON-ESSENTIAL REGION IN THE TERMINAL REPEATS OF FOWLPOX VIRUS AND DEMONSTRATION OF PROTECTIVE IMMUNITY INDUCED BY THE RECOMBINANT", JOURNAL OF GENERAL VIROLOGY, vol. 71, no. 3, 1990, pages 621 - 628, XP009037597, ISSN: 0022-1317 *
LAIDLAW STEPHEN M ET AL: "Comparison of the genome sequence of FP9, an attenuated, tissue culture-adapted European strain of Fowlpox virus, with those of virulent American and European viruses.", JOURNAL OF GENERAL VIROLOGY, vol. 85, no. 2, February 2004 (2004-02-01), pages 305 - 322, XP002299586, ISSN: 0022-1317 *
LAIDLAW STEPHEN M ET AL: "Fowlpox virus encodes nonessential homologs of cellular alpha-SNAP, PC-1, and an orphan human homolog of a secreted nematode protein", JOURNAL OF VIROLOGY, vol. 72, no. 8, August 1998 (1998-08-01), pages 6742 - 6751, XP002299583, ISSN: 0022-538X *
MEYER H ET AL: "MAPPING OF DELETIONS IN THE GENOME OF THE HIGHLY ATTENUATED VACCINIA VIRUS MVA AND THEIR INFUENCE ON VIRULENCE", JOURNAL OF GENERAL VIROLOGY, READING, BERKS, GB, vol. 72, 1991, pages 1031 - 1038, XP000952390, ISSN: 0022-1317 *
QINGZHONG Y ET AL: "Protection against turkey rhinotracheitis pneumovirus (TRTV) induced by a fowlpox virus recombinant expressing the TRTV fusion glycoprotein (F).", VACCINE. MAY 1994, vol. 12, no. 6, May 1994 (1994-05-01), pages 569 - 573, XP002299582, ISSN: 0264-410X *
SPEHNER D ET AL: "CONSTRUCTION OF FOWLPOX VIRUS VECTORS WITH INTERGENIC INSERTIONS: EXPRESSION OF THE BETA-GALACTOSIDASE GENE AND THE MEASLES VIRUS FUSION GENE", JOURNAL OF VIROLOGY, NEW YORK, US, US, vol. 64, no. 2, 1 February 1990 (1990-02-01), pages 527 - 533, XP000749308, ISSN: 0022-538X *
SUTTER GERD ET AL: "Nonreplicating vaccinia vector efficiently expresses recombinant genes", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 89, no. 22, 1992, pages 10847 - 10851, XP002299581, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
GB2402391A (en) 2004-12-08
GB0312803D0 (en) 2003-07-09
WO2004108940A2 (fr) 2004-12-16

Similar Documents

Publication Publication Date Title
WO2000003030A3 (fr) Poxvirus recombine du raton laveur et ses utilisations comme vaccin chez des especes mammiferes et aviaires
WO2003092592A3 (fr) Vaccin tetravalent contre la dengue contenant une suppression commune de 30 nucleotides dans la 3'-utr de types 1, 2, 3 et 4 de la dengue ou des virus antigenes chimeriquesde la dengue de types 1, 2, 3 et 4
WO2003047617A3 (fr) Vaccin
WO2003092594A8 (fr) Vecteurs viraux et procedes de production et d'utilisation de ceux-ci
EP1098961A4 (fr) Interferon induisant des virus attenues mis au point par genie genetique
WO2001039797A3 (fr) Clones infectieux
EP1256628A3 (fr) ARN polymerase NS5B du virus de la hepatite C et mutants derivés de la polymerase
WO2003087313A3 (fr) Procedes d'amelioration de l'exsertion de la soie de mais lorsqu'elle est sujette a des agressions
WO2003023040A3 (fr) Mutants du virus de la vaccine obtenus par inactivation de mva-e3l et leur utilisation
WO2001000234A3 (fr) Procedes et compositions pour la mise au point de vaccins attenues
WO2004087062A3 (fr) Compositions contenant un virus syncytial respiratoire de la souche 9320 du sous-groupe b, et procedes associes
WO2005011571A3 (fr) Proteines du noyau du virus de l'hepatite utilisees comme plateformes de vaccins et leur utilisation
EP1845164A3 (fr) Promoteurs pour expression dans le virus de la vaccine ankara modifié
WO2002027007A3 (fr) Production de vecteurs viraux
DE60040662D1 (de) Vektor zur integration von heterologen sequenzen in poxvirusgenomen
WO2004108940A3 (fr) Produits
WO2002042450A8 (fr) Promoteurs du virus bacilliforme de la canne a sucre isoles a partir de cultivars de canne a sucre
WO2000066743A3 (fr) Vecteurs d'expression virale
WO2003033692A3 (fr) Utilisation du promoteur tardif e2 adenoviral
WO2001059108A3 (fr) Inhibiteurs d'apoptose
IL139372A0 (en) Recombinant virus expressing foreign dna encoding feline cd80, feline ctla-4 or feline cd86 and uses thereof
WO2003047532A3 (fr) Compositions et methodes destinees a l'utilisation therapeutique d'une sequence associee au gene atonal pour une maladie gastro-intestinale
WO2004048403A3 (fr) La proteine 4a non structurelle (ns4a) du virus de l'hepatite c en tant qu'element activateur
HUP0103871A2 (hu) Rekombináns CELO-vírus és CELO vírus DNS
EP1074624A4 (fr) Gene 62 de la souche oka du virus de la varicelle attenue et procede d'identification de la souche du virus pour le vaccin de la varicelle vivant attenue a l'aide de ce gene

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase